Related Experiment Video
Updated: Jun 10, 2025
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
14.8K
JAK Inhibitors for Myelofibrosis: Strengths and Limitations
K Thaw1, C N Harrison2, P Sriskandarajah1
1Department of Haematology, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK.
Current Hematologic Malignancy Reports
|October 14, 2024
Summary
Janus kinase inhibitors (JAKis) offer benefits for myelofibrosis patients, but challenges like resistance persist. Newer, selective JAKis and combination therapies show promise for improved treatment outcomes.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Myelofibrosis (MF) treatment has evolved with Janus kinase (JAK) inhibitor development.
- JAK inhibitors target the JAK2 V617F mutation central to MF pathogenesis.
Purpose of the Study:
- To critically analyze the strengths and limitations of current JAK inhibitors for myelofibrosis.
- To review recent advancements in JAK inhibitor therapy for MF.
Main Methods:
- Literature review of current JAK inhibitors used in myelofibrosis treatment.
- Analysis of clinical data regarding efficacy, durability, and resistance patterns.
Main Results:
- JAK inhibitors improve symptom burden, spleen size, and survival in MF patients.
- Treatment resistance and limited response durability remain significant challenges.
- Development of selective JAK inhibitors and combination therapies are emerging strategies.
Conclusions:
- While JAK inhibitors have transformed MF care, challenges persist.
- Optimized treatment strategies involving selective JAK inhibitors and combination therapies offer future hope.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:31Types of Intermediate Filaments
3.6K
The intermediate filaments are an essential component of the cytoskeleton. Presently six types of intermediate filament have been identified. Type I and II are acidic and basic keratin proteins. Type III is of mesodermal origin and comprises four proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Vimentin is commonly found in mesenchymal cells, desmin in muscle cells, GFAP in astrocytes, while peripherin is found in peripheral nervous system neurons (PNS). Type...
3.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
633
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
633
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
143
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
143